<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185714</url>
  </required_header>
  <id_info>
    <org_study_id>10840098-604.01.1</org_study_id>
    <nct_id>NCT04185714</nct_id>
  </id_info>
  <brief_title>THE EFFECTS OF KINESIO®TAPING IN PATIENTS WITH MIGRAINE</brief_title>
  <official_title>THE EFFECTS OF KINESIO®TAPING ON PAIN, DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH MIGRAINE: A RANDOMISED SINGLE-BLIND, PLACEBO-CONTROLLED TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipol University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with migraine, neck pain and trigger points in the neck muscles are common in&#xD;
      clinical practice. This study was to investigate whether kinesiotaping applied to the&#xD;
      cervical muscles has a clinical effect on pressure pain threshold, disability and quality of&#xD;
      life in patients with migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with episodic migraine who were followed up by department of neurology in regional&#xD;
      hospital will be included in the study. The Clinical Research Ethics committee approved the&#xD;
      study (protocol no 10840098-604.01.1-E.6803).&#xD;
&#xD;
      Inclusion criterias are aged between 18-55 years, the patients with episodic migraine by&#xD;
      neurologist according to ICHD-3 Beta criteria, patients with episodic migraine and associated&#xD;
      neck pain, headache frequency in 1 month &lt; 15 days and pain severity according to VAS above&#xD;
      40 mm.&#xD;
&#xD;
      Exclusion criterias are other headache types, contraindication for KT technique, cervical&#xD;
      disc disorders, systemic rheumatic disease, fibromyalgia pain syndrome, myofascial pain&#xD;
      syndrome, temporamandibular joint dysfunction, pregnancy, overuse medication, patients who&#xD;
      had gotten rehabilitation programme before at least 3 months ago and anaesthetic blockage&#xD;
      before at least 6 months ago.&#xD;
&#xD;
      All patients will allocate three groups. The patients with episodic migraine were randomly&#xD;
      assigned to control group (n=20), placebo group (n=20) and experimental group (n= 20).&#xD;
&#xD;
      Outcome measures Demographic data and headache characteristics of the patients (frequency,&#xD;
      duration, onset of headache, family history, onset age of headache, pain triggering factors,&#xD;
      and localization of headache), presence of neck pain and disability of the last 1 month will&#xD;
      evaluate before and after 6 weeks of treatment via self-administered questionnaire. Pressure&#xD;
      Pain Algometry (Baseline Dolorimeter), Visual Analogue Scale (VAS), Neck Disability Index,&#xD;
      Migraine Disability Assessment Scale (MIDAS) and Short Form-36 (SF-36) will use as the&#xD;
      assessment method in the 6-week follow-up.&#xD;
&#xD;
      Intervention All two groups will give a 6-week exercise programme for 2 days per week.&#xD;
      Exercise programme that included neck and head isotonic and isometric exercises show by&#xD;
      physiotherapist. The participants will administer the exercises every day for 45 minutes.&#xD;
      Sham taping will be applied for the placebo group. Kinesiotaping will be applied to the&#xD;
      trapezius and deep cervical muscles twice a week for experimental group. The taping replace&#xD;
      every 3 days.&#xD;
&#xD;
      Statistical Analyses Data will be expressed as mean, standard deviation and median.&#xD;
      Significance between pre- and post-treatment pain, disability and quality of life variables&#xD;
      was statistically significant with Paired Stutend's t - test and Wilcoxon signed rank tests;&#xD;
      The differences between groups will be analysed using the Kruskal-Wallis-test to determine&#xD;
      statistical significance. For statistical significance p &lt;0.05 probability value will be&#xD;
      accepted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analog scale</measure>
    <time_frame>Pretreatment- Posttreatment ( 6 weeks later)</time_frame>
    <description>Headache pain severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visual analog scale</measure>
    <time_frame>Pretreatment-Posttreatment (6 weeks later)</time_frame>
    <description>Neck pain severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Dolorimeter</measure>
    <time_frame>pretreatment- Posttreatment ( 6 weeks later)</time_frame>
    <description>pressure pain threshold</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical data questionnaire</measure>
    <time_frame>pretreatment- Posttreatment ( 6 weeks later)</time_frame>
    <description>clinical data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short form-36</measure>
    <time_frame>pretreatment - Post treatment (6 weeks later)</time_frame>
    <description>quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIDAS</measure>
    <time_frame>Pretreatment</time_frame>
    <description>Migraine Disability Assessment Scale (not score scale It describes the total of 3-month headache )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck Disability Index</measure>
    <time_frame>pretreatment - Post treatment (6 weeks later)</time_frame>
    <description>questionnaire to assess neck pain related disability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Migraine</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group will be applied Kinesotaping , exercise programme will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Exercise programme will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham taping will be applied, exercise programme will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kinesiotaping</intervention_name>
    <description>Kinesiotaping (KT) is an approach that supports injured muscles and joints and helps relieve pain.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>exercise</other_name>
    <other_name>sham taping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo taping</intervention_name>
    <description>sham taping</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  age between 18-55 years,&#xD;
&#xD;
          -  the patients with episodic migraine by neurologist according to ICHD-3 Beta criteria,&#xD;
&#xD;
          -  headache frequency in 1 month &lt; 15 days and&#xD;
&#xD;
          -  pain severity according to VAS above 40 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other headache disorders&#xD;
&#xD;
          -  disc disorders,&#xD;
&#xD;
          -  systemic rheumatic disease, fibromyalgia pain syndrome, myofascial pain syndrome,&#xD;
&#xD;
          -  temporamandibular joint dysfunction,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  overuse medication,&#xD;
&#xD;
          -  patients who had gotten rehabilitation programme before at least 3 months ago and&#xD;
&#xD;
          -  anaesthetic blockage before at least 6 months ago.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duzce University</name>
      <address>
        <city>Düzce</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medipol University</investigator_affiliation>
    <investigator_full_name>Esra Kınacı</investigator_full_name>
    <investigator_title>Research Asistant</investigator_title>
  </responsible_party>
  <keyword>Episodic Migraine</keyword>
  <keyword>Kinesiotape</keyword>
  <keyword>Pain</keyword>
  <keyword>Physiotherapy</keyword>
  <keyword>Disability</keyword>
  <keyword>Pressure Pain Threshold</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

